Cancer treatment protocols and best practices are ever-evolving and there have been some major changes in the ovarian cancer space in just the past few years alone. To break down the latest updates, SurvivorNet hosted a panel of experts to explore what has changed for patients and physicians — and what the future of ovarian cancer care looks like.
NOW
PLAYING
PLAYING
The Different Phases Of Chronic Myeloid Leukemia & Their Management
NOW
PLAYING
PLAYING
Distinguishing Between Acute And Chronic Myeloid Leukemia
NOW
PLAYING
PLAYING
A Better Medication For Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma: Zanubrutinib
NOW
PLAYING
PLAYING
Zanubrutinib: A Better Medication For Chronic Lymphocytic Leukemias & Small Lymphocytic Lymphomas
NOW
PLAYING
PLAYING
Active Surveillance For Chronic Lymphocytic Leukemia (CLL)
NOW
PLAYING
PLAYING
The Evolving Management of Anemia in Myelofibrosis
MHQ: Clinical Intelligence
Powered by SurvivorNet
Rapid evidence support for real-world oncology decisions.
Clinical scenarios relevant to this topic:
Are there specific recent advancements in treatment protocols for ovarian cancer that have shown improved patient outcomes?
How do the latest findings impact the decision-making process for personalized treatment plans in ovarian cancer?
What role do emerging therapies play in the future landscape of ovarian cancer management?
